Journal article
In vivo TSPO imaging in patients with multiple sclerosis: A brain PET study with [18F]FEDAA1106
A Takano, F Piehl, J Hillert, A Varrone, S Nag, B Gulyás, P Stenkrona, VL Villemagne, CC Rowe, R Macdonell, NA Tawil, T Kucinski, T Zimmermann, M Schultze-Mosgau, A Thiele, A Hoffmann, C Halldin
Ejnmmi Research | Published : 2013
Abstract
Background: The activation of microglia, in general, and the upregulation of the translocator protein (18 kDa) (TSPO) system, in particular, are key features of neuroinflammation, of which the in vivo visualization and quantitative assessment are still challenging due to the lack of appropriate molecular imaging biomarkers. Recent positron emission tomography (PET) studies using TSPO radioligands such as [11C]PK11195 and [111C]PBR28 have indicated the usefulness of these PET biomarkers in patients with neuroinflammatory diseases, including multiple sclerosis (MS). [18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO. In the present study, we aimed at ..
View full abstractGrants
Funding Acknowledgements
The authors thank all the members of the PET group at the Karolinska Institutet PET Center for their assistance in the PET study. The study was sponsored by Bayer HealthCare.